The Shifting Tides of Drug Discovery: Evolving Pharmacokinetic Strategies in APAC CRO Partnerships

The shift from small-molecule drugs to complex biologics is transforming pharmacokinetics, especially in the APAC region, enhancing CRO partnerships and drug development strategies.

Life Sciences Review | Tuesday, February 10, 2026

The pharmaceutical landscape is shifting from conventional small-molecule drugs to complex biologics, reshaping every stage of drug development with profound implications for pharmacokinetics. This evolution is especially evident within the expanding Asia-Pacific (APAC) region, where a synergistic relationship has developed between drug developers and Contract Research Organizations (CROs). Pharmacokinetic assessment strategies are undergoing a substantial change, transcending established models for small molecules to accommodate the complex and detailed requirements of large-molecule biologics.

The Pharmacokinetics of Small Molecules vs. Biologics

For decades, the pharmaceutical industry's pipeline was dominated by small-molecule drugs. These chemically synthesized compounds, with their low molecular weight, generally exhibit predictable pharmacokinetic profiles. Their absorption is often straightforward, distribution throughout the body is relatively uniform, and well-characterized enzymatic pathways in the liver primarily handle their metabolism. This inherent predictability allowed for the development of standardized and relatively streamlined pharmacokinetic study designs. The analytical methodologies, although sophisticated, were centered mainly on techniques such as liquid chromatography-mass spectrometry (LC-MS), which are adept at quantifying small molecules in biological matrices.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The advent of biologics—a diverse class of therapies that includes monoclonal antibodies, vaccines, and cell and gene therapies—has fundamentally altered the pharmacokinetic equation. These large, complex molecules, produced in living systems, behave vastly differently in the human body. Their size often precludes oral administration, necessitating intravenous or subcutaneous injection. Distribution is typically more limited, with these macromolecules usually confined to the vascular and interstitial spaces.

Crucially, the metabolism and elimination of biologics follow entirely different pathways compared to their small-molecule counterparts. Instead of hepatic enzyme degradation, biologics are often cleared through proteolytic pathways, target-mediated drug disposition, and uptake by the reticuloendothelial system. This complexity introduces a host of new considerations for pharmacokinetic studies, demanding a more tailored and sophisticated approach. The inherent immunogenicity of some biologics also adds another layer of complexity, requiring careful monitoring of anti-drug antibodies (ADAs), which can significantly impact a drug's pharmacokinetic profile and efficacy.

The Evolving Role of CROs in the APAC Region

The growing prominence of biologics has coincided with the maturation and expansion of the CRO industry in the APAC region. CROs provided essential but often standardized services for small-molecule development. However, the unique challenges posed by biologics have created a demand for specialized expertise that many pharmaceutical companies, as well as small and mid-sized enterprises, may not possess in-house. This has elevated the role of APAC CROs from service providers to strategic partners in the drug development journey.

These specialized CROs offer a comprehensive suite of services tailored to the intricacies of biologics. This includes the development and validation of precise and sensitive bioanalytical assays, such as ligand-binding assays (LBAs), which are essential for accurately quantifying large molecules in biological samples. They also possess the expertise to design and execute complex pharmacokinetic studies that can adequately characterize the absorption, distribution, metabolism, and excretion of these novel therapeutics. Furthermore, their experience in navigating the evolving regulatory landscape for biologics in various APAC countries is invaluable to their partners.

The collaborative model between pharmaceutical companies and CROs in the APAC region is fostering an environment of innovation. By outsourcing their pharmacokinetic studies to these specialized organizations, drug developers can access cutting-edge technologies and a deep pool of scientific talent. This partnership allows for greater efficiency and flexibility in drug development, enabling companies to focus on their core competencies while leveraging the specialized capabilities of their CRO partners.

Integrated Strategies for a New Era of Medicine

The evolution of pharmacokinetic strategies in the context of APAC CRO partnerships will continue to be driven by the expanding pipeline of even more complex biologics, including next-generation antibodies, cell-based therapies, and RNA-based medicines. The focus will increasingly shift towards a more integrated and holistic understanding of a drug's behavior in the body. This will involve the closer integration of pharmacokinetic data with pharmacodynamic (PD) and immunogenicity assessments to build comprehensive models that can predict a drug's efficacy and safety with greater accuracy.

Advanced bioanalytical techniques, such as hybrid LC-MS/LBA assays and high-resolution mass spectrometry, will become more commonplace, enabling a deeper characterization of biologics and their metabolites. Furthermore, the application of sophisticated modeling and simulation techniques will play an increasingly critical role in optimizing study designs, predicting human pharmacokinetics from preclinical data, and informing dose selection.

The transition from small molecules to biologics has fundamentally transformed pharmacokinetic strategies. The APAC region, with its expanding pharmaceutical landscape and proficient CROs, is spearheading this evolution. The collaborative alliances established between pharmaceutical developers and these specialized entities are not only expediting the development of novel therapies but are also influencing the trajectory of pharmacokinetic science. As the industry continues to advance medical innovation, these evolving strategies and partnerships will be pivotal in delivering the next generation of transformative treatments to patients globally.

More in News

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Specials

The Shifting Tides of Drug Discovery: Evolving Pharmacokinetic Strategies in APAC CRO Partnerships

The shift from small-molecule drugs to complex biologics is transforming pharmacokinetics, especially in the APAC region, enhancing CRO partnerships and drug development strategies.